BOSTON- Androgen deprivation therapy - one of the most common treatments for prostate cancer - may increase the risk of death from heart disease in patients over age 65, according to a new study by researchers at Dana-Farber Cancer Institute, Brigham and Women's Hospital and other institutions. The study results were based on data from CaPSURE, a national registry of men with prostate cancer. Although the findings need to be confirmed in clinical trials, the study authors state that oncologists should weigh the benefits of androgen deprivation therapy, or ADT, against the risk of heart problems in older prostate cancer patients. The researchers will present their study at the Prostate Cancer Symposium in Orlando, Fla., 1:30 pm on Saturday, Feb. 24. The symposium is sponsored by the American Society of Clinical Oncology, the American Society for Therapeutic Radiology and Oncology and the Society of Urologic Oncology.